BR9712765A - Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos - Google Patents

Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos

Info

Publication number
BR9712765A
BR9712765A BR9712765-5A BR9712765A BR9712765A BR 9712765 A BR9712765 A BR 9712765A BR 9712765 A BR9712765 A BR 9712765A BR 9712765 A BR9712765 A BR 9712765A
Authority
BR
Brazil
Prior art keywords
compositions
processes
fkbp12
affinity
compounds
Prior art date
Application number
BR9712765-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert E Zelle
Michael Su
Original Assignee
Vertex Pharmaceutucals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25009484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9712765(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharmaceutucals Inc filed Critical Vertex Pharmaceutucals Inc
Publication of BR9712765A publication Critical patent/BR9712765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR9712765-5A 1996-11-13 1997-11-13 Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos BR9712765A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/748,447 US5840736A (en) 1996-11-13 1996-11-13 Methods and compositions for stimulating neurite growth
PCT/US1997/020866 WO1998020891A1 (en) 1996-11-13 1997-11-13 Methods and compositions for stimulating neurite growth using compounds with affinity for fkbp12 in combination with neurotrophic factors

Publications (1)

Publication Number Publication Date
BR9712765A true BR9712765A (pt) 1999-10-26

Family

ID=25009484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712765-5A BR9712765A (pt) 1996-11-13 1997-11-13 Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos

Country Status (32)

Country Link
US (3) US5840736A (enExample)
EP (1) EP0946190B1 (enExample)
JP (1) JP2001504470A (enExample)
KR (1) KR100544451B1 (enExample)
CN (1) CN1168442C (enExample)
AP (1) AP9901518A0 (enExample)
AR (1) AR011278A1 (enExample)
AT (1) ATE250424T1 (enExample)
AU (1) AU724833B2 (enExample)
BG (1) BG64670B1 (enExample)
BR (1) BR9712765A (enExample)
CA (1) CA2270634A1 (enExample)
CO (1) CO4930260A1 (enExample)
CZ (1) CZ296058B6 (enExample)
DE (1) DE69725169T2 (enExample)
DK (1) DK0946190T3 (enExample)
EA (1) EA004247B1 (enExample)
ES (1) ES2206753T3 (enExample)
HU (1) HU226728B1 (enExample)
IL (1) IL129555A (enExample)
IN (1) IN183740B (enExample)
IS (1) IS2057B (enExample)
NO (1) NO328030B1 (enExample)
NZ (1) NZ335394A (enExample)
PL (1) PL190903B1 (enExample)
PT (1) PT946190E (enExample)
SK (1) SK284535B6 (enExample)
TR (1) TR199901034T2 (enExample)
TW (1) TW513302B (enExample)
UA (1) UA63926C2 (enExample)
WO (1) WO1998020891A1 (enExample)
ZA (1) ZA9710256B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
AU1708099A (en) 1998-06-03 1999-12-20 Amgen, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
TR200100122T2 (tr) 1998-07-17 2001-08-21 Agouron Pharmaceuticals.Inc. Nöral büyüme ve uzama için bileşikler, kompozisyonlar, yöntemler
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6228872B1 (en) * 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
WO2000033814A2 (en) * 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system
EP1140844A1 (en) * 1999-01-08 2001-10-10 Vertex Pharmaceuticals Incorporated Process for the formation of intermediates useful for the preparation of pharmaceuticals
JP2003503480A (ja) * 1999-07-06 2003-01-28 バーテックス ファーマシューティカルズ インコーポレイテッド ニューロン活性を有するｎ−ヘテロ環誘導体
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AU6497200A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
DK1227859T3 (da) * 1999-11-12 2006-12-11 Alcon Inc Neurophilinligander til behandling af okulære tilstande
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
AU1464101A (en) 1999-12-21 2001-07-03 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
EP1575477B1 (en) * 2001-05-25 2012-04-25 Cornell Research Foundation, Inc. HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR
MXPA03011095A (es) * 2001-05-29 2005-04-28 Guilford Pharm Inc Metodo para tratar una lesion nerviosa causada por cirugia.
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
BRPI0720473A2 (pt) * 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
AU2019271189A1 (en) 2018-05-15 2021-01-07 Lloyd Hung Loi TRAN Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US9604852B2 (en) * 2012-09-28 2017-03-28 Dic Corporation α-alumina particles and method for manufacturing the same

Also Published As

Publication number Publication date
KR20000068962A (ko) 2000-11-25
CA2270634A1 (en) 1998-05-22
IS2057B (is) 2005-10-14
SK284535B6 (sk) 2005-06-02
DE69725169D1 (de) 2003-10-30
CN1168442C (zh) 2004-09-29
IN183740B (enExample) 2000-04-01
NO328030B1 (no) 2009-11-16
ATE250424T1 (de) 2003-10-15
US6284778B1 (en) 2001-09-04
JP2001504470A (ja) 2001-04-03
PL190903B1 (pl) 2006-02-28
HU226728B1 (en) 2009-08-28
KR100544451B1 (ko) 2006-01-24
NZ335394A (en) 2000-06-23
PT946190E (pt) 2004-02-27
AP9901518A0 (en) 1999-06-30
IL129555A0 (en) 2000-02-29
BG103429A (en) 2000-04-28
TW513302B (en) 2002-12-11
IS5032A (is) 1999-04-21
AR011278A1 (es) 2000-08-16
PL333270A1 (en) 1999-11-22
NO992138L (no) 1999-07-13
HUP0001219A2 (hu) 2000-11-28
CZ296058B6 (cs) 2006-01-11
DE69725169T2 (de) 2004-07-15
HUP0001219A3 (en) 2001-12-28
WO1998020891A1 (en) 1998-05-22
AU5258998A (en) 1998-06-03
US5840736A (en) 1998-11-24
AU724833B2 (en) 2000-09-28
ZA9710256B (en) 1998-05-28
EA199900464A1 (ru) 2000-02-28
EP0946190B1 (en) 2003-09-24
SK62899A3 (en) 2000-04-10
DK0946190T3 (da) 2003-12-08
CZ168399A3 (cs) 1999-08-11
CO4930260A1 (es) 2000-06-27
EA004247B1 (ru) 2004-02-26
EP0946190A1 (en) 1999-10-06
ES2206753T3 (es) 2004-05-16
NO992138D0 (no) 1999-05-03
TR199901034T2 (xx) 1999-07-21
BG64670B1 (bg) 2005-11-30
UA63926C2 (uk) 2004-02-16
IL129555A (en) 2005-08-31
CN1239433A (zh) 1999-12-22
HK1022851A1 (en) 2000-08-25
US6172086B1 (en) 2001-01-09

Similar Documents

Publication Publication Date Title
BR9712765A (pt) Processos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos
BR9713037A (pt) Métodos e composições para estimulação do crescimento de neurites utilizando compostos com afinidade para fkbp12 em combinação com fatores neurotróficos
BR9712947A (pt) Processo e composições para a estimulação do crescimento de neuritos.
BR9811923A (pt) Compostos possuindo atividade neuronal
EP1666037A3 (en) Compositions for stimulating neurite growth
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BRPI9815772A (pt) emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
DE69434414D1 (de) Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
BRPI9909282A (pt) compostos de éter aminociclohexílicos e usos dos mesmos.
BR9714415A (pt) Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38
BR9707958A (pt) Composto, composição farmacêutica, e, processo para tratar hiperalgesia em um paciente.
KR900700617A (ko) 뼈 및 연골 유도 조성물
BR0016150A (pt) Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
CA2248139A1 (en) Methods of alleviating neuropathic pain using prosaposin-derived peptides
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
CA2120303A1 (en) Cyclic adhesion inhibitors
BR0315981A (pt) Composições para tratamento de tecidos que contêm diferentes silicones, processo para a sua preparação e método para a sua utilização
PT1066056E (pt) Composto de ferro-dextrano para utilizacao como componente de uma composicao terapeutica para a profilaxia ou tratamento da carencia de ferro processo de producao do referido composto de ferro-dextrano e utilizacao desse mesmo composto na preparacao de uma composicao terapeutica de administracao parenterica
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
EE04953B1 (et) Tsinkhaluronaadi kasutamine ja meetod ravimkoostise valmistamiseks
AU6076886A (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO COM BASE NOS ARTIGOS 8O E 13O DA LEI 9.279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]